Microbial immune suppression mediated by direct engagement of inhibitory Fc receptor

Journal of Immunology

Volumn 177, Issue 10, 2006, Pages 6842-6851

  Monari, Claudia ^a   Kozel, Thomas R ^b   Paganelli, Francesca ^a   Pericolini, Eva ^a   Perito, Stefano ^a   Bistoni, Francesco ^a   Casadevall, Arturo ^c   Vecchiarelli, Anna ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; GLUCURONOXYLOMANNAN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; POLYSACCHARIDE; PROTEIN; PROTEIN SHIP; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 33750819880     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.10.6842     Document Type: Article

References (46)

1. Monari, C., T. R. Kozel, A. Casadevall, D. Pietrella, B. Palazzetti, and A. Vecchiarelli. 1999. B7 costimulatory ligand regulates development of the T cell response to Cryptococcus neoformans. Immunology 98: 27-35.
2. Pietrella, D., C. Monari, C. Retini, B. Palazzetti, T. R. Kozel, and A. Vecchiarelli. 1999. HIV type 1 envelope glycoprotein gp120 induces development of a T helper type 2 response to Cryptococcus neoformans. AIDS 13: 2197-2207.
3. Vecchiarelli, A., D. Pietrella, P. Lupo, F. Bistoni, D. C. McFadden, and A. Casadevall. 2003. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation. J. Leukocyte Biol. 74: 370-378.
4. Syme, R. M., T. F. Bruno, T. R. Kozel, and C. H. Mody. 1999. The capsule of Cryptococcus neoformans reduces T lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody. Infect. Immun. 67: 4620-4627.
5. Retini, C., A. Vecchiarelli, C. Monari, F. Bistoni, and T. R. Kozel. 1998. Encapsulation of Cryptococcus neoformans with glucuronoxylomannan inhibits the antigen-presenting capacity of monocytes. Infect. Immun. 66: 664-669.
6. Retini, C., A. Casadevall, D. Pietrella, C. Monari, B. Palazzetti, and A. Vecchiarelli. 1999. Specific activated T cells regulate IL-12 production by human monocytes stimulated with Cryptococcus neoformans. J. Immunol. 162: 1618-1623.
7. Monari, C., E. Pericolini, G. Bistoni, A. Casadevall, T. R. Kozel, and A. Vecchiarelli. 2005. Cryptococcus neoformans capsular glucuronoxylomannan induces expression of fas ligand in macrophages. J. Immunol. 174: 3461-3468.
8. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Down-regulation by cryptococcal polysaccharide of tumor necrosis factor α and interleukin-1β secretion from human monocytes. Infect. Immun. 63: 2919-2923.
9. Vecchiarelli, A., C. Retini, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Purified capsular polysaccharide of Cryptococcus neoformans induces interleukin-10 secretion by human monocytes. Infect. Immun. 64: 2846-2849.
10. Retini, C., T. R. Kozel, D. Pietrella, C. Monari, F. Bistoni, and A. Vecchiarelli. 2001. Interdependency of interleukin-10 and interleukin-12 in regulation of T cell differentiation and effector function of monocytes in response to stimulation with Cryptococcus neoformans. Infect. Immun. 69: 6064-6073.
11. Dong, Z. M., and J. W. Murphy. 1997. Cryptococcal polysaccharides bind to CD18 on human neutrophils. Infect. Immun. 65: 557-563.
12. Shoham, S., C. Huang, J. M. Chen, D. T. Golenbock, and S. M. Levitz. 2001. Toll-like receptor 4 mediates intracellular signaling without TNF-α release in response to Cryptococcus neoformans polysaccharide capsule. J. Immunol. 166: 4620-4626.
13. Monari, C., F. Bistoni, A. Casadevall, E. Pericolini, D. Pietrella, T. R. Kozel, and A. Vecchiarelli. 2005. Glucuronoxylomannan, a microbial compound, regulates expression of costimulatory molecules and cytokine production in macrophages. J. Infect. Dis. 191: 127-137.
14. Daeron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15: 203-234.
15. Van den Herik-Oudijk, I. E., P. J. Capel, T. van der Bruggen, and J. G. Van de Winkel. 1995. Identification of signaling motifs within human FcγRIIa and FcγRIIb isoforms. Blood 85: 2202-2211.
16. Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science 290: 84-89.
17. Tridandapani, S., K. Siefker, J. L. Teillaud, J. E. Carter, M. D. Wewers, and C. L. Anderson. 2002. Regulated expression and inhibitory function of FcγRIIb in human monocytic cells. J. Biol. Chem. 277: 5082-5089.
18. Amigorena, S., C. Bonnerot, J. R. Drake, D. Choquet, W. Hunziker, J. G. Guillet, P. Webster, C. Sautes, I. Mellman, and W. H. Fridman. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256: 1808-1812.
19. Muta, T., T. Kurosaki, Z. Misulovin, M. Sanchez, M. C. Nussenzweig, and J. V. Ravetch. 1994. A 13-amino-acid motif in the cytoplasmic domain of FcγRIIB modulates B-cell receptor signalling. Nature 369: 340.
20. Feldmesser, M., A. Mednick, and A. Casadevall. 2002. Antibody-mediated protection in murine Cryptococcus neoformans infection is associated with pleotrophic effects on cytokine and leukocyte responses. Infect. Immun. 70: 1571-1580.
21. Dromer, F., J. Salamero, A. Contrepois, C. Carbon, and P. Yeni. 1987. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55: 742-748.
22. Eckert, T. F., and T. R. Kozel. 1987. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect. Immun. 55: 1895-1899.
23. Beenhouwer, D. O., S. Shapiro, M. Feldmesser, A. Casadevall, and M. D. Scharff. 2001. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans. Infect. Immun. 69: 6445-6455.
24. Yuan, R. R., A. Casadevall, J. Oh, and M. D. Scharff. 1997. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice. Proc. Natl. Acad. Sci. USA 94: 2483-2488.
25. Vecchiarelli, A., C. Retini, C. Monari, and A. Casadevall. 1998. Specific antibody to Cryptococcus neoformans alters human leukocyte cytokine synthesis and promotes T cell proliferation. Infect. Immun. 66: 1244-1247.
26. Vecchiarelli, A. 2000. Immunoregulation by capsular components of Cryptococcus neoformans. Med. Mycol. 38: 407-417.
27. Vecchiarelli, A., C. Monari, C. Retini, D. Pietrella, B. Palazzetti, L. Pitzurra, and A. Casadevall. 1998. Cryptococcus neoformans differently regulates B7-1 (CD80) and B7-2 (CD86) expression on human monocytes. Eur. J. Immunol. 28: 114-121.
28. Monari, C., A. Casadevall, D. Pietrella, F. Bistoni, and A. Vecchiarelli. 1999. Neutrophils from patients with advanced human immunodeficiency virus infection have impaired complement receptor function and preserved Fey receptor function. J. Infect. Dis. 180: 1542-1549.
29. Monari, C., A. Casadevall, C. Retini, F. Baldelli, F. Bistoni, and A. Vecchiarelli. 1999. Antibody to capsular polysaccharide enhances the function of neutrophils from patients with AIDS against Cryptococcus neoformans. AIDS 13: 653-660.
30. Plesner, A., C. J. Greenbaum, and A. Lemmark. 2001. Low serum conditions for in vitro generation of human macrophages with macrophage colony stimulating factor. J. Immunol. Methods 249: 53-61.
31. Cherniak, R., E. Reiss, M. E. Slodki, R. D. Plattner, and S. O. Blumer. 1980. Structure and antigenic activity of the capsular polysaccharide of Cryptococcus neoformans serotype A. Mol. Immunol. 17: 1025-1032.
32. Houpt, D. C., G. S. Pfrommer, B. J. Young, T. A. Larson, and T. R. Kozel. 1994. Occurrences, immunoglobulin classes, and biological activities of antibodies in normal human serum that are reactive with Cryptococcus neoformans glucuron-oxylomannan. Infect. Immun. 62: 2857-2864.
33. Mukherjee, S., S. C. Lee, and A. Casadevall. 1995. Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages. Infect. Immun. 63: 573-579.
34. Mukherjee, S., S. Lee, J. Mukherjee, M. D. Scharff, and A. Casadevall. 1994. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect. Immun. 62: 1079-1088.
35. Monari, C., C. Retini, A. Casadevall, D. Netski, F. Bistoni, T. R. Kozel, and A. Vecchiarelli. 2003. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils. Eur. J. Immunol. 33: 1041-1051.
36. Pauwels, R., J. Balzarini, M. Baba, R. Snoeck, D. Schols, P. Herdewijn, J. Desmyter, and E. De Clercq. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20: 309-321.
37. Vecchiarelli, A. 2005. The cellular responses induced by the capsular polysaccharide of Cryptococcus neoformans differ depending on the presence or absence of specific protective antibodies. Curr. Mol. Med. 5: 413-420.
38. Baeuerle, P. A., and T. Henkel. 1994. Function and activation of NF-κB in the immune system. Annu. Rev. Immunol. 12: 141-179.
39. Zandi, E., D. M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin. 1997. The IκB kinase complex (IKK) contains two kinase subunits, IKKα and IKKβ, necessary for IκB phosphorylation and NF-κB activation. Cell 91: 243-252.
40. Larsen, R. A., P. G. Pappas, J. Perfect, J. A. Aberg, A. Casadevall, G. A. Cloud, R. James, S. Filler, and W. E. Dismukes. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob. Agents Chemother. 49: 952-958.
41. Muzio, M., N. Polntarutti, D. Bosisio, M. K. Prahladan, and A. Mantovani. 2000. Toll like receptor family (TLT) and signalling pathway. Eur. Cytokine Netw. 11: 489-490.
42. Casadevall, A., and L. A. Pirofski. 2003. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol. 24: 474-478.
43. Grinsell, M., L. C. Weinhold, J. E. Cutler, Y. Han, and T. R. Kozel. 2001. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages. J. Infect. Dis. 184: 479-487.
44. Lee, S. C., A. Casadevall, and D. W. Dickson. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J Pathol. 148: 1267-1274.
45. Engelhardt, W., H. Gorczytza, A. Butterweck, H. Monkemann, and J. Frey. 1991. Structural requirements of the cytoplasmic domains of the human macrophage Fey receptor IIa and B cell Fey receptor IIb2 for the endocytosis of immune complexes. Eur. J. Immunol. 21: 2227-2238.
46. March, M. E., and K. Ravichandran. 2002. Regulation of the immune response by SHIP. Semin. Immunol. 14: 37-47.